Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib, IIa Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Chemotherapy-Naive Stage IV Non-Small Cell Lung Cancer

NCT01004731 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT01004731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01004731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib, IIa Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Chemotherapy-Naive Stage IV Non-Small Cell Lung Cancer
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2001
Completion date
January 31, 2006
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv non-small cell lung cancer